NKGN

0.00300.00%
AT

Anthony T. Reder

Member of Scientific Advisory Board

Dr. Anthony T. Reder, M. D., serves as Member of Scientific Advisory Board at NKGen Biotech, Inc. since March 2023. Dr. Reder is a Professor of Neurology at the University of Chicago Medical Center directing the Neurology and Inflammatory Disease Infusion Center. He is an internationally recognized expert in neuroimmunology with primary expertise in the clinical and molecular intersection between inflammation and brain damage and as well as how the immune system may protect and repair the damaged brain. He has been a clinical leader in the development of many approved immune therapies for multiple sclerosis. He serves as Associate Editor of Medlink Corporation. Dr. Reder serves as Associate Professor of Neurology of University of Chicago. He has been Editorial Board Member of Neuro-immunology of Medlink Corporation since 2000. Dr. Reder has participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta (Betaseron), plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya) and ozanimod (Zeposia), estriol (the pregnancy hormone), natalizumab (Tysabri), and anti-CD20 therapies (Ocrevus), plus drugs for severe pain in MS such as misoprostol. Current clinical trials include evaluating drugs that repair myelin—which insulates and enhances nerve firing and drugs that enhance neuron function. Dr. Reder obtained his MD degree from University of Michigan, completed his residency in Neurology at University of Minnesota and a fellowship in NeuroImmunology at University of Chicago where he is now a Professor of Neurology.

Positions